Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Supralethal whole body irradiation and isologous marrow transplantation in man.J Clin Invest. 1959; 38: 1709-1716
- Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the histocompatibility and alternate stem cell source working Committee of the international bone marrow transplant Registry.J Clin Oncol. 2004; 22: 4872-4880
- Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors.Biol Blood Marrow Transplant. 2008; 14: 44-53
- Allogeneic hematopoietic stem-cell transplantation from haploidentical donors using 'ex-vivo' T-cell depletion in pediatric patients with hematological malignancies: state of the art review.Curr Opin Oncol. 2018; 30: 396-401
- Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science. 2002; 295: 2097-2100
- Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.Lancet Haematol. 2020; 7: e134-e145
- Peripheral blood stem cells for allogeneic transplantation: a review.Stem Cells. 2001; 19: 108-117
- Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and international bone marrow transplant Registry working Committee on alternative donor and stem cell sources.N Engl J Med. 2000; 342: 1846-1854
- Eurocord transplant group and the European blood and marrow transplantation GroupOutcome of cord-blood transplantation from related and unrelated donors.N Engl J Med. 1997; 337: 373-381
- Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.Leuk Lymphoma. 2009; 50: 1566-1572
- The role of the endothelium in the short-term complications of hematopoietic SCT.Transplant. 2011; 46: 1495-1502
- Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).Bone Marrow Transplant. 2015; 50: 781-789
- Post-bone marrow transplant thrombotic microangiopathy.Bone Marrow Transplant. 2016; 51: 891-897
- Outcomes after induction failure in childhood acute lymphoblastic leukemia.N Engl J Med. 2012; 366: 1371-1381
- The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.Blood Cancer J. 2019; 9: 10
- Improving CAR T cell therapy by optimizing critical quality attributes.Semin Hematol. 2020; 57: 33-38
- Improving CAR T-cells: the next generation.Semin Hematol. 2020; https://doi.org/10.1053/j.seminhematol.2020.07.002
- Utilization of CAR T cell therapy in pediatric patients.Semin Oncol Nurs. 2019; 35: 150929
- Clinical utilization of Chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert Opinion from the European Society for blood and marrow transplantation and the American Society for blood and marrow transplantation.Biol Blood Marrow Transplant. 2019; 25: e76-e85
- Biology and clinical application of CAR T cells for B cell malignancies.Int J Hematol. 2016; 104: 6-17
- ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol Blood Marrow Transplant. 2019; 25: 625-638
- Managing cytokine release syndrome associated with novel T cell-engaging therapies.Cancer J. 2014; 20: 119-122
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.Blood. 2008; 112: 3959-3964
- Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med. 2018; 378: 439-448
- Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med. 2019; 380: 45-56
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial.Lancet Oncol. 2019; 20: 31-42
- Chimeric antigen receptor T cells: a race to revolutionize cancer therapy.Transfus Med Hemother. 2019; 46: 15-24
- Human FoxP3+ regulatory T cells in systemic autoimmune diseases.Autoimmun Rev. 2011; 10: 744-755
- Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol. 1995; 155: 1151-1164
- Cell-Based Therapies with T regulatory cells.BioDrugs. 2017; 31: 335-347
- CD4+CD25highCD127low/-FoxP3+ regulatory T-cell population in acute leukemias: a review of the literature.J Immunol Res. 2019; 2019: 2816498
- First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.Clin Immunol. 2009; 133: 22-26
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.Blood. 2011; 117: 1061-1070
- Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.Blood. 2016; 127: 1044-1051
- CD4+CD25highCD127low/-FoxP3+ regulatory T cell Subpopulations in the bone marrow and peripheral blood of children with ALL: brief Report.J Immunol Res. 2018; 2018: 1292404
- CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction.Clin Immunol. 2004; 112: 258-267
- Ontogeny of tumor-associated CD4+CD25+Foxp3+ T-regulatory cells.Immunol Invest. 2016; 45: 729-745
- Critical stoichiometric ratio of CD4(+) CD25(+) FoxP3(+) regulatory T cells and CD4(+) CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia.Immunology. 2014; 142: 124-139
- Change of CD4(+) CD25(+) regulatory T cells and NK Cells in peripheral blood of children with acute leukemia and its possible significance in tumor immunity.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010; 18: 709-713
- NK cells for cancer immunotherapy.Nat Rev Drug Discov. 2020; 19: 200-218
- Single degranulations in NK cells can mediate target cell killing.J Immunol. 2018; 200: 3231-3243
- Cytomegalovirus infection drives avidity selection of natural killer cells.Immunity. 2019; 50: 1381-1390.e5
- Replicative potential of human natural killer cells.Br J Haematol. 2009; 145: 606-613
- NK cell therapy for hematologic malignancies.Int J Hematol. 2018; 107: 262-270
- J Immunol. 2002; 169: 239-247
- Killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors.Exp Hematol. 2012; 40: 882-891
- Natural killer cells in pediatric acute lymphoblastic leukemia patients at diagnosis demonstrate an inhibitory phenotype and reduced cytolytic capacity.Blood. 2013; 122: 1397
- Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation.Front Immunol. 2017; 8: 465
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.Blood. 2014; 123: 3855-3863
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.Blood. 2005; 105: 3051-3057
- Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.Blood. 2017; 130: 1857-1868
- 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.Cytotherapy. 2017; 19: 1225-1232
- Generation of BiKEs and TriKEs to Improve NK cell-mediated targeting of tumor cells.Methods Mol Biol. 2016; 1441: 333-346
- TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.Hematology. 2017; 22: 136-144
- Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells.Lancet. 1981; 2: 327-331
- Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells.Blood. 1983; 61: 341-348
- Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum.Blood. 1994; 84: 3948-3955
- Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.N Engl J Med. 1998; 339: 1186-1193
- Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients.Bone Marrow Transplant. 2015; 50: S6-S10
- A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation.Cytotherapy. 2007; 9: 746-754
- Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.Biol Blood Marrow Transplant. 2015; 21: 130-136
- αβ T cell-depleted haploidentical hematopoietic stem cell transplantation without antithymocyte globulin in children with chemorefractory acute myelogenous leukemia.Biol Blood Marrow Transplant. 2019; 25: e179-e182
- Reciprocal interactions between commensal bacteria and γδ intraepithelial lymphocytes during mucosal injury.J Immunol. 2009; 182: 3047
- Cellular and gene therapy guidances. U.S. Food and Drug Administration.(Available at:) (Accessed August 16, 2020)
- Foundation for the accreditation of cellular therapy. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).Cytotherapy. 2003; 5: 299-305
- Foundation for the accreditation of cellular therapy. FACT.(Available at:) (Accessed August 16, 2020)
- International standards for hematopoietic cellular therapy product collection, processing, and administration (Seventh edition version 7.0).(Available at:)http://www.factwebsite.org/ctstandards/(Accessed August 10, 2020)Date: 2018
- Common standards for cellular therapies (Second edition).(Available at:) (Accessed August 10, 2020)
- Standards for immune effector cells (first edition version 1.1).(Available at:)http://www.factwebsite.org/iecstandards/(Accessed August 10, 2020)Date: 2018
Article info
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
